News & Press: Latest News

MDMA Submits Comments to USPTO to Strengthen MedTech Property Rights

Monday, July 9, 2018  
Share |
MDMA Submits Comments to USPTO to Strengthen MedTech Property Rights

MDMA urged the U.S. Patent and Trademark Office (USPTO) today to strengthen intellectual property rights for medical technology innovators by restoring balance to the Patent Trial and Appeals Board (PTAB) proceedings and slow the decline in patent rights in the United States.

In May, the USPTO submitted a proposed rule to change the claim construction standard in inter partes review, post-grant review, and the transitional program for covered business patents proceedings before the PTAB.

If adopted, the rule would change the standard for claims construction at PTAB proceedings from the current "broadest reasonable interpretation" to the more narrow "Phillips" standard used in
district courts.

To read MDMA's comments to the USPTO, please CLICK HERE.